Epitalon
Pending PCACAlso known as: Epithalon, Epithalone, Ala-Glu-Asp-Gly
Anti-Aging & LongevityLast reviewed: April 28, 2026
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
Mechanism of Action
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
Common Uses
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
Known Risks
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
Regulatory Status
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
Get notified when the PCAC decides on Epitalon
Scheduled review: July 24, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
5–10 mg
Frequency
Once daily for 10–20 days (course-based)
Cycle Length
10–20 day course, 1–2x per year
Typically used in short intensive courses rather than continuous cycling. Often stacked with Pinealon for combined neuroprotective and anti-aging effects.
Intranasal
Typical Dose
1–2 mg
Frequency
Once daily
Cycle Length
10–20 days
Lower bioavailability than injectable but more convenient. Less common.
Related Compounds
Research References
Related Articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
regulatory · 5 min read
What Is Epitalon? Mechanism, Uses, Risks, and FDA Status
guide · 5 min read
The July 2026 PCAC Meeting: What's at Stake for BPC-157, TB-500, Semax, and More
regulatory · 7 min read
FDA Removes 12 Peptides from Category 2: What It Actually Means
regulatory · 6 min read
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.